Focused On-demand Library for Signal recognition particle subunit SRP54

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P61011

UPID:

SRP54_HUMAN

Alternative names:

Signal recognition particle 54 kDa protein

Alternative UPACC:

P61011; B2R759; B4DUW6; P13624

Background:

The Signal recognition particle subunit SRP54, a 54 kDa protein, plays a pivotal role in the cotranslational targeting of secretory and membrane proteins to the endoplasmic reticulum (ER). It is a key component of the signal recognition particle (SRP) complex, facilitating the interaction with the SRP receptor and the subsequent translocation of proteins into the ER. SRP54's GTPase activity is crucial for this process, enabling the dynamic rearrangement necessary for efficient protein targeting.

Therapeutic significance:

SRP54's involvement in severe congenital neutropenia underscores its therapeutic potential. By understanding its role in granulocytic cell proliferation, neutrophil migration, and exocrine pancreas development, novel strategies for treating this hematopoiesis disorder could be developed, offering hope for patients suffering from this condition.